Research Pathways

Bringing gene and cell therapies from the lab bench to patients is a complex process.The Research Pathways directory contains resources to help guide various stakeholders interested in therapy development through this process. 

The Research Pathways is centred around the legal and regulatory aspects that are required for cell and gene therapy development in Europe, from binding law, guidelines and recommendations, then further expanded to additional aspects including ethics, scientific developments, commercialisation, health economics and more. 

Learn more about Research Pathways

Additional navigation options

More ways to navigate Research Pathways

Key Pathways Resources

Signposting to key resources on ATMP development

Case Studies

Learn from specific development cases and relevant resources

Patient and Public Involvement

ATMP Engage Patient and Public Involvement Directory

Actors & Networks

Mapping the stakeholders in Europe and beyond

Filter by

Theme
Target audience
Region
Resource type
Organisation type
Disease of focus
Réinitialiser
Showing 4 of 4
EuroGCT Resource

Dossier de demande d'autorisation de mise sur le marché

  • EU and UK
  • 2022
  • EuroGCT
Marketing authorisation application requires from the applicant the submission of a file containing documentation and data related to the medicinal product to be authorised. The file must comply with the Common Technical Document (CTD), a set of specifications for the marketing authorisation application dossier. Under the centralised procedure the application is submitted under a standardised electronic format, the electronic Common Technical Document (eCTD), through an online portal.
Read this resource

Theme

  • Tout afficher 2
  • Commercialisation
  • Market access for ATMPs
EuroGCT Resource

Procédure centralisée pour les médicaments de thérapie innovante

  • EU and UK
  • 2022
  • EuroGCT
The centralised procedure allows an ATMP to be commercialised and made available to patients and healthcare professionals throughout the entire European Union on the basis of a single marketing authorisation at the European level.
Read this resource

Theme

  • Tout afficher 2
  • Commercialisation
  • Market access for ATMPs
EuroGCT Resource

Autorisation de mise sur le marché conditionnelle des médicaments de thérapie innovante

  • EU and UK
  • 2023
  • EuroGCT
To facilitate early patient access to medicinal products, marketing authorisation (MA) can be granted through specific regulatory mechanisms offered by European Union law. When an Advanced Therapy Medicinal Product (ATMP) addresses an unmet medical need of patients, a conditional marketing authorisation may be granted on the basis of less comprehensive data than usually required.
Read this resource

Theme

  • Tout afficher 2
  • Commercialisation
  • Market access for ATMPs
EuroGCT Resource

Autorisation de mise sur le marché sous circonstances exceptionnelles des médicaments de technologie innovante

  • EU and UK
  • 2023
  • EuroGCT
To facilitate early patient access to medicinal products, marketing authorisation (MA) can be granted through specific regulatory mechanisms offered by European Union law. A marketing authorisation under exceptional circumstances for medicinal products may be granted when the applicant is unable to provide comprehensive data on the efficacy and safety under normal conditions of use, because the indication to be treated is too rare, the present state of scientific knowledge is insufficient to provide comprehensive information, or it would be unethical to collect this information.
Read this resource

Theme

  • Tout afficher 2
  • Commercialisation
  • Market access for ATMPs
Retour en haut de page